Adaptive 3D microelectrode array for organoid models of neurological and neurodegenerative diseases
Official title: The first adaptable 3D-formfitting microelectrode array for organoid-based models of neurological and neurodegenerative diseases
Funded at Bmseed, LLC · NIH-11311188 · Data updated 2026-11-12
A new 3D microelectrode platform helps brain organoids from patient cells to model neurological and neurodegenerative diseases for better drug screening.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bmseed, LLC NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project start | September 18, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $700,518 |
| NIH project number | 2R44NS124469-02 |
| Project ID | NIH-11311188 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals whose iPSC-derived brain organoids model Alzheimer’s-related conditions or similar neurodegenerative diseases.
✕Less likely to help
Direct benefits may be limited for people without organoid-based disease models or if organoid approaches do not translate clinically.
What this research studies
This project develops a 3D, adaptable microelectrode array to study brain organoids derived from human iPSCs. It aims to improve pre-clinical drug screening by capturing more realistic electrical activity in organoids, especially for diseases like Alzheimer’s and related conditions. Researchers will test how well the device records network activity in organoids and how this data can inform drug candidates before human trials.
Why it matters
Potential benefit: If successful, patients could see faster development of effective therapies with more accurate preclinical testing.
How similar studies have gone: Preclinical organoid models and advanced electrophysiology have shown promise, but 3D MEAs remain a novel approach with potential for better human-relevant readouts.
Where this research is happening
-
Bmseed, LLC
Tempe, United States Active
Researchers
- Principal investigator: Graudejus, Oliver — Bmseed, LLC
- Study coordinator: Graudejus, Oliver
Related research
Other NIH-funded projects on the same topics.
-
Developing small molecules to treat TDP-43 related brain diseases
A potential new drug candidate (XL20) for diseases like Alzheimer’s and other dementias linked to TDP-43 protein problems is being developed and refined for people who live with these conditions.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
-
Targeting RNA Splicing Abnormalities in ALS/FTD
A research team aims to understand and correct abnormal RNA splicing in ALS and related brain diseases to help patients in the future.
-
Blood-brain barrier–friendly imaging agents for neurodegenerative diseases
A researcher team will test new imaging agents that can cross the brain barrier to help detect Alzheimer’s and related diseases earlier and more accurately.
-
Brain cell–derived EV markers to differentiate Alzheimer’s and related dementias
A Mayo Clinic team is testing brain-cell–specific tiny particles in blood to tell apart Alzheimer’s disease and similar dementias using advanced machine-learning analysis.
-
Fisetin approach to reduce vulnerability to community infections in aging veterans
A patient-friendly look at a study testing whether the natural compound fisetin can help aging Veterans stay healthier when they face common infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.